- Home
- PKE vs AVIR Comparison
PKE vs AVIR Comparison
Compare PKE & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PKE
- AVIR
- Stock Information
- Founded
- PKE 1954
- AVIR 2012
- Country
- PKE United States
- AVIR United States
- Employees
- PKE N/A
- AVIR N/A
- Industry
- PKE Military/Government/Technical
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- PKE Industrials
- AVIR Health Care
- Exchange
- PKE Nasdaq
- AVIR Nasdaq
- Market Cap
- PKE 285.7M
- AVIR 273.7M
- IPO Year
- PKE N/A
- AVIR 2020
- Fundamental
- Price
- PKE $13.40
- AVIR $2.96
- Analyst Decision
- PKE
- AVIR Hold
- Analyst Count
- PKE 0
- AVIR 1
- Target Price
- PKE N/A
- AVIR $6.88
- AVG Volume (30 Days)
- PKE 46.6K
- AVIR 274.5K
- Earning Date
- PKE 01-14-2025
- AVIR 03-06-2025
- Dividend Yield
- PKE 3.71%
- AVIR N/A
- EPS Growth
- PKE N/A
- AVIR N/A
- EPS
- PKE 0.36
- AVIR N/A
- Revenue
- PKE $61,420,000.00
- AVIR N/A
- Revenue This Year
- PKE N/A
- AVIR N/A
- Revenue Next Year
- PKE N/A
- AVIR N/A
- P/E Ratio
- PKE $37.44
- AVIR N/A
- Revenue Growth
- PKE 15.45
- AVIR N/A
- 52 Week Low
- PKE $11.96
- AVIR $2.75
- 52 Week High
- PKE $16.62
- AVIR $4.15
- Technical
- Relative Strength Index (RSI)
- PKE 44.86
- AVIR 41.74
- Support Level
- PKE $13.64
- AVIR $2.90
- Resistance Level
- PKE $14.27
- AVIR $3.29
- Average True Range (ATR)
- PKE 0.34
- AVIR 0.12
- MACD
- PKE 0.06
- AVIR -0.01
- Stochastic Oscillator
- PKE 40.16
- AVIR 17.95
About PKE Park Aerospace Corp.
Park Aerospace Corp designs develop and manufactures engineered, advanced composite materials and composite structures and assemblies and low-volume tooling for the aerospace markets and prototype tooling for such structures and assemblies. Geographically, the company derives a majority of revenue from North America and also has a presence in a company operates its business in Asia and Europe. It offers advanced composite Prepregs for Aircraft Structures and Interiors, Sigma Strut and Alpha Strut.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).